A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results
Abstract Background Regorafenib is one of several FDA‐approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype‐specific data regarding kinase inhibitor activity in sarcomas. We report results of a single arm, phase II trial of regorafenib in advanced Ewing family...
Main Authors: | Steven Attia, Vanessa Bolejack, Kristen N. Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T. Loggers, Michael B. Livingston, Jennifer Wright, Sant P. Chawla, Scott H. Okuno, Denise K. Reinke, Richard F. Riedel, Lara E. Davis, Christopher W. Ryan, Robert G. Maki |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5044 |
Similar Items
-
CIC-DUX4 sarcoma: A case report and review of the literature
by: Chang-Hung Liao, et al.
Published: (2022-01-01) -
CIC-Rearranged Sarcomas: An Intriguing Entity That May Lead the Way to the Comprehension of More Common Cancers
by: Caterina Mancarella, et al.
Published: (2022-11-01) -
DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
by: Emanuele Mocciaro, et al.
Published: (2021-11-01) -
Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group
by: Mehdi Brahmi, et al.
Published: (2023-04-01) -
CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas
by: Arnaud Bakaric, et al.
Published: (2024-01-01)